Recent studies into retatruptide peptide demonstrate notable outlook for managing obesity and type disease. The peptide, a dual activator of GLP-1 and glucose-dependent insulinotropic polypeptide, looks to provide greater weight loss and glucose control in contrast to existing treatments. Further clinical trials are required to fully assess its saf